                         SEQUENCE LISTING

<110>  Virginia Commonwealth University
 
<120>  HUMAN CYTOMEGALOVIRUS VACCINE

<130>  02940718ta

<150>  US 61/381,280
<151>  2010-09-09

<160>  9     

<170>  PatentIn version 3.5

<210>  1
<211>  20
<212>  PRT
<213>  Cytomegalovirus

<400>  1

Ser Trp Ser Thr Leu Thr Ala Asn Gln Asn Pro Ser Pro Pro Trp Ser 
1               5                   10                  15      


Lys Leu Thr Tyr 
            20  


<210>  2
<211>  20
<212>  PRT
<213>  Cytomegalovirus

<400>  2

Pro Trp Ser Thr Leu Thr Ala Asn Gln Asn Pro Ser Pro Pro Trp Ser 
1               5                   10                  15      


Lys Leu Thr Tyr 
            20  


<210>  3
<211>  20
<212>  PRT
<213>  Cytomegalovirus

<400>  3

Pro Trp Phe Thr Leu Thr Ala Asn Gln Asn Pro Ser Pro Pro Trp Ser 
1               5                   10                  15      


Lys Leu Thr Tyr 
            20  


<210>  4
<211>  20
<212>  PRT
<213>  Cytomegalovirus

<400>  4

Pro Trp Ser Thr Leu Thr Ala Asn Lys Asn Pro Ser Pro Pro Trp Ser 
1               5                   10                  15      


Lys Leu Thr Tyr 
            20  


<210>  5
<211>  20
<212>  PRT
<213>  Cytomegalovirus

<400>  5

Pro Trp Ser Thr Leu Thr Ala Asn Gln Asn Pro Ser Pro Leu Trp Ser 
1               5                   10                  15      


Lys Leu Thr Tyr 
            20  


<210>  6
<211>  17
<212>  PRT
<213>  Cytomegalovirus

<400>  6

Ser Asp Phe Arg Arg Gln Asn Arg Arg Gly Gly Thr Asn Lys Arg Thr 
1               5                   10                  15      


Thr 
    


<210>  7
<211>  20
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic consensus sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Residue 1 (X1)can be S or P

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Residue 3 (X2)can be S or F

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  Residue 9 (X3)can be Q or K

<400>  7

Xaa Trp Xaa Thr Leu Thr Ala Asn Xaa Asn Pro Ser Pro Pro Trp Ser 
1               5                   10                  15      


Lys Leu Thr Tyr 
            20  


<210>  8
<211>  216
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic fusion protein

<400>  8

Met Asp Ile Asp Pro Tyr Lys Glu Phe Gly Ser Ser Tyr Gln Leu Leu 
1               5                   10                  15      


Asn Phe Leu Pro Leu Asp Phe Phe Pro Asp Leu Asn Ala Leu Val Asp 
            20                  25                  30          


Thr Ala Thr Ala Leu Tyr Glu Glu Glu Leu Thr Gly Arg Glu His Cys 
        35                  40                  45              


Ser Pro His His Thr Ala Ile Arg Gln Ala Leu Val Cys Trp Asp Glu 
    50                  55                  60                  


Leu Thr Lys Leu Ile Ala Trp Met Ser Ser Asn Ile Thr Ser Gly Ile 
65                  70                  75                  80  


Pro Glu Asp Glu Ser Trp Ser Thr Leu Thr Ala Asn Gln Asn Pro Ser 
                85                  90                  95      


Pro Pro Trp Ser Lys Leu Thr Tyr Glu Glu Gly Thr Val Arg Thr Ile 
            100                 105                 110         


Ile Val Asn His Val Asn Asp Thr Trp Gly Leu Lys Val Arg Gln Ser 
        115                 120                 125             


Leu Trp Phe His Leu Ser Cys Leu Thr Phe Gly Gln His Thr Val Gln 
    130                 135                 140                 


Glu Phe Leu Val Ser Phe Gly Val Trp Ile Arg Thr Pro Ala Pro Tyr 
145                 150                 155                 160 


Arg Pro Pro Asn Ala Pro Ile Leu Ser Thr Leu Pro Glu His Thr Val 
                165                 170                 175     


Ile Arg Arg Arg Gly Gly Ala Arg Ala Ser Arg Ser Pro Arg Arg Arg 
            180                 185                 190         


Thr Pro Ser Pro Arg Arg Arg Arg Ser Gln Ser Pro Arg Arg Arg Arg 
        195                 200                 205             


Ser Gln Ser Pro Ser Ala Asn Cys 
    210                 215     


<210>  9
<211>  651
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic nucleic acid sequence encoding fusion protein

<400>  9
atggacatag atccgtataa agagtttggc tcctcctatc agctgctgaa cttcctgccg       60

ctggattttt tcccggatct gaatgcgctg gttgataccg ccaccgcgct gtatgaagaa      120

gaactgacgg gtcgtgaaca ctgctcccct caccatactg ctattcgtca ggccctggtg      180

tgctgggacg aactgactaa actgatcgcc tggatgagct ccaacattac gtctggaatt      240

ccggaggacg agtcctggtc caccctgacc gctaaccaga acccgtcccc gccgtggtcc      300

aaactgacct acgaggaggg taccgtaaga acaatcattg taaatcatgt caatgatacc      360

tggggactta aggtgagaca aagtttatgg tttcatttgt catgtctcac tttcggacaa      420

catacagttc aagaattttt agtaagtttt ggagtatgga tcaggactcc agctccatat      480

agacctccta atgcacccat tctctcgact cttccggaac atactgttat tcgccgtcgc      540

ggtggtgcac gtgcttctcg cagcccacgt cgtcgcactc catctccgcg ccgtcgtaga      600

tctcaatctc cgcgtcgccg tcgctctcaa tctccatctg ccaactgctg a               651


